

NC Medicaid Pharmacy Prior Approval Request Immunomodulators: Renflexis

Beneficiary Information

1. Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:
Prescriber Information		
6. Prescribing Provider NPI #:		
		e #: Ext
Drug Information		
		10. Quantity Per 30 Days:
11. Length of Therapy (in days)։ 🗆 սր Other	o to 30 Days 🔲 60 Days 🖂 90 Days 🗆] 120 Days □ 180 Days □ 365 Days □
<u> </u>		
Clinical Information		
2. Is the beneficiary not on another 3. Has the beneficiary been consider 4. Has the beneficiary been tested w 5. Has the beneficiary experienced in No 6. Is beneficiary unable to receive the or rapidly progressing disease? ☐ Ye 7. Has the beneficiary had a trial and Cosentyx, Enbrel or Humira? ☐ Yes	rith Hep B SAG and Core Ab?	☐ Yes ☐ No tent tuberculosis infection? ☐ Yes ☐ No
2. Is the beneficiary not on another3. Has the beneficiary been consider4. Has the beneficiary been tested w	osis of moderate to severe Crohn's Dise injectable biologic immunomodulator? red and screened for the presence of late with Hep B SAG and Core Ab? Yes N	☐ Yes ☐ No tent tuberculosis infection? ☐ Yes ☐ No
2. Is the beneficiary not on another3. Has the beneficiary been consider4. Has the beneficiary been tested w	osis of moderate to severe Crohn's Dise injectable biologic immunomodulator? red and screened for the presence of late with Hep B SAG and Core Ab? Yes N	☐ Yes ☐ No tent tuberculosis infection? ☐ Yes ☐ No



Pharmacy PA Call Center: 1-855-258-1593

NC Medicaid Pharmacy Prior Approval Request

Request for Plaque Psoriasis (Adult)
1. Does the beneficiary have a documented definitive diagnosis of moderate-to-severe Chronic Plaque Psoriasis?
Yes 🗆 No
2. Is the beneficiary 18 years of age or older? ☐ Yes ☐ No
3. Is the beneficiary not on another injectable biologic immunomodulator? Ves No
4. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection (not required
for Otezla)? ☐ Yes ☐ No
5. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No
6. Does the beneficiary have a body surface area (BSA) involvement of at least 3%? ☐ Yes ☐ No
7. Does the beneficiary have involvement of the palms, soles, head and neck, or genitalia, causing disruption in
normal daily activities and/or employment? Yes No
8. Has the beneficiary failed to respond to, or has been unable to tolerate phototherapy and ONE of the following
medications or beneficiary has contraindications to these treatments: Soriatane (acitretin), Methotrexate, and/or
Cyclosporine? ☐ Yes ☐ No
9. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try
Cosentyx, Enbrel or Humira? Yes No
10. Are the beneficiaries, providers, and pharmacies utilizing Siliq registered appropriately in the Siliq Risk Evaluation
and Mitigation Strategy Program (REMS program) ? \square Yes \square No
Request for Psoriatic Arthritis
1. Does the beneficiary have a documented definitive diagnosis of Psoriatic Arthritis? ☐ Yes ☐ No
2. Is the beneficiary 18 years of age or older (OR 2 years or older for Simponi Aria)? Yes No
3. Is the beneficiary not on another injectable biologic immunomodulator? ☐ Yes ☐ No
4. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? \square Yes \square No
5. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
6. Does the beneficiary have a documented inadequate response or inability to take methotrexate? \Box Yes \Box No
7. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try
Cosentyx, Enbrel or Humira? Yes No
Request for Rheumatoid Arthritis
1. Does the beneficiary have a diagnosis of Rheumatoid Arthritis? Yes No
2. Is the beneficiary not on another injectable biologic immunomodulator? Ves No
3. Has the beneficiary been considered and screened for the presence of latent tuberculosis? \square Yes \square No
4. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No
5. Has the beneficiary experienced a therapeutic failure/inadequate response with methotrexate or at least one
disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine) ? Yes
No
6. Is the beneficiary unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications
or intolerabilities? Yes No
7. Does the beneficiary have clinical evidence of severe or rapidly progressing disease? Yes No
8. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try Enbrel or
Humira? ☐ Yes ☐ No



Pharmacy PA Call Center: 1-855-258-1593

NC Medicaid Pharmacy Prior Approval Request

Request for Ulcerative Colitis (Adult)
 Does the beneficiary have a diagnosis of ulcerative colitis? ☐ Yes ☐ No Is the beneficiary not on another injectable biologic immunomodulator? ☐ Yes ☐ No Has the beneficiary been considered and screened for the presence of latent tuberculosis? ☐ Yes ☐ No Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ Yes ☐ No
5. Has the beneficiary had a trial and failure of Humira or a clinical reason beneficiary cannot try Humira? \Box Yes \Box No.
Signature of Prescriber: Date:
(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.